Skip to content
x.com· @ · X·· 2026-04-23Score60
Body

Lack of a good model is a major bottleneck for research about how to optimize immunotherapy efficacy while limiting toxicity, and reverse-translational approaches will be vital for testing tissue-specific combination therapy, our Dr. Kristen Pauken said at #AACR26. Learn more about her work: https://t.co/mnKofFbxEU #EndCancer

Heat 18 · 13 likes · 1 reply · 4 reposts

Source: x.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org